U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H33N3O2
Molecular Weight 383.527
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ORG-28611

SMILES

COC1=C2N(CC3CCCCC3)C=C(C(=O)N4CCN(C)[C@@H](C)C4)C2=CC=C1

InChI

InChIKey=ONXJNAIZJKLJGA-KRWDZBQOSA-N
InChI=1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H33N3O2
Molecular Weight 383.527
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

ORG-28611 (SCH-900,111) is a potent cannabinoid receptor full agonist, developed by Organon International for treatment pain. In preclinical studies, Org 28611 exhibited high affinity for both CB1 and CB2 cannabinoid receptors, as determined by radioligand competition binding assays and rapidly metabolized by mouse and human hepatic microsomes and showed higher total levels in the brain compared to plasma. In clinical trials, Org 28611 does not provide enough sedation for outpatient surgical procedures, does not induce anterograde amnesia and causes undesirable subjective effects at higher doses. However, bolus doses up to 3 μ/kg (with maximum initial plasma concentrations of 24 ng/mL) or mean plasma levels up to 4 ng/mL are well tolerated and make it worthwhile to further explore the analgesic or antiemetic properties.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
25.12 nM [EC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
24 ng/mL
3 μg/kg single, intravenous
ORG-28611 blood
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
Single Intravenous Dose of ORG 28611 3 mcg/kg
Route of Administration: Intravenous
In Vitro Use Guide
Chinese Hamster Ovary (CHO) cells expressing the human CB1 receptor were used for activity evaluation. Cells were suspended in phenol red / serum free DMEM / F-12 nut mix containing penicillin / streptomycin (50U/50 ¬g/ml) and fungizone (1 ¬g/ml) and seeded into 96 well plates at a density of 3 x 10^4 cells per well (100 ¬l final volume). Cells were incubated overnight (approx. 18 hours at 37°C, 5% CO2/95% air) prior to assay. The test compound (10mM solution in DMSO) was diluted in F12 Nut Mix to give a range of stock solutions from 0.11 mM to 0.11 nM. The stock solutions (10mkl) were added directly to the relevant wells. The plates were incubated at 37°C for 5 hours to allow agonist-induced expression of the luciferase enzyme. Under subdued light, LucLite substrate (Packard; reconstituted as per manufacturer’s instructions; 100 mkl) was added to each well. Plates were covered with Top Seal and then incubated at room temperature for 5 minutes before counting on the Packard TopCount (single photon counting, 0.01 minute count time, 5 minute count delay).
Substance Class Chemical
Record UNII
1U7V49NTQG
Record Status Validated (UNII)
Record Version